Drug Profile

HUEXC 030

Alternative Names: HUEXC-030

Latest Information Update: 08 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Orient Pharma
Class Antituberculars; Hepatoprotectants; Small molecules
Mechanism of Action Amidohydrolase inhibitors; Cytochrome P-450 CYP2E1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

08 Jan 2025 No development reported - Phase-II/III for Liver disorders (Second-line therapy or greater) in Taiwan (PO)
03 May 2021 Suspended - Phase-II/III for Liver disorders in Taiwan (PO) (NCT02467608)
30 Dec 2019 No development reported - Phase-II/III for Liver disorders in Taiwan (PO)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com